Global Autologous Cell Therapy Market Size Study, by Application, by Source, by End-Use, and Regional Forecasts 2022-2032

Description

The Global Autologous Cell Therapy Market is valued approximately at USD 4.32 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 22.20% over the forecast period 2024-2030. Autologous cell therapy involves using a patient's cells, typically derived from tissues like bone marrow or blood, to treat various medical conditions. These cells are harvested from the patient, processed to isolate specific types of cells (such as stem cells or immune cells), and then reintroduced into the patient's body. Autologous cell therapy is used in treatments for conditions such as cancer, autoimmune diseases, and certain genetic disorders, aiming to harness the body's own regenerative or immune capabilities for therapeutic benefit. The Global Autologous Cell Therapy Market is experiencing robust growth driven by several key factors. The rise in the geriatric population and the increasing prevalence of chronic diseases such as cancer and neurodegenerative disorders are significantly driving the market growth.

The rise in the geriatric population and the increasing prevalence of chronic diseases such as cancer and neurodegenerative disorders are significant contributors. The aging population leads to a higher incidence of age-related ailments, necessitating advanced treatment options. Simultaneously, the growing number of patients diagnosed with chronic conditions highlights the urgent need for innovative therapies, making autologous cell therapy a critical area of development and investment in the healthcare sector. Moreover, the market is witnessing technological advancements in cell isolation and expansion, making these therapies more accessible and cost-effective. For instance, in March 2024, the FDA approved Breyanzi by Bristol Myers Squibb for adults with CLL or SLL that is relapsed or refractory. This CAR-T cell therapy is given as a one-time infusion. The clinical trials and market expansions of key players are enhancing the market dynamics. Moreover, increasing investment and research in autologous cell therapies and adoption of personalized medicine are creating new opportunities to the market growth. However, the high cost of autologous cell therapy, Stringent Regulatory Requirements are hindering the market growth during the projected period 2024-2032.

Key regions considered for the global Autologous Cell Therapy market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America dominated the market, driven by the presence of major market players and advanced healthcare infrastructure. The U.S. held the largest share in the North American region and is expected to grow rapidly over the forecast period due to FDA approvals and increasing investments. Europe also shows significant potential, with supportive regulatory environments and substantial funding for research. The Asia-Pacific region is anticipated to witness the fastest growth due to the rising burden of diseases and strong research activities in autologous cell therapies.

Major market players included in this report are:

BrainStorm Cell Therapeutics
Holostem Terapie Avanzate S.R.L
Pharmicell Co. Inc
Opexa Therapeutics
Caladrius Biosciences Inc
U.S. Stem Cell Inc
Lonza Group AG
Bristol Myers Squibb
Novartis AG

The detailed segments and sub-segment of the market are explained below:

By Application:

Cancer
Neurodegenerative Disorders
Cardiovascular Disorders
Autoimmune Disorders
Orthopedics
Wound Healing
Others

By Source:

Bone Marrow
Peripheral Blood
Adipose Tissue
Others

By End-Use:

Hospitals
Academics & Research
Others

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Autologous Cell Therapy Market Executive Summary

1.1. Global Autologous Cell Therapy Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Application
- 1.3.2. By Source
- 1.3.3. By End-Use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Autologous Cell Therapy Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Autologous Cell Therapy Market Dynamics

3.1. Market Drivers
- 3.1.2. Rising Geriatric Population
- 3.1.3 Prevalence of Chronic Diseases
- 3.1.3. Technological Advancements and Innovation in Cell Therapies
3.2. Market Challenges
- 3.2.1. High Costs and Complex Manufacturing Processes
- 3.2.2. Stringent Regulatory Requirements
3.3. Market Opportunities
- 3.3.2. Increasing Investment and Research in Autologous Cell Therapies
- 3.3.3. Adoption of Personalized Medicine

Chapter 4. Global Autologous Cell Therapy Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Autologous Cell Therapy Market Size & Forecasts by Application 2022-2032

5.1. Segment Dashboard
5.2. Global Autologous Cell Therapy Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Cancer
- 5.2.2. Neurodegenerative Disorders
- 5.2.3. Cardiovascular Disorders
- 5.2.4. Autoimmune Disorders
- 5.2.5. Orthopedics
- 5.2.6. Wound Healing
- 5.2.7. Others

Chapter 6. Global Autologous Cell Therapy Market Size & Forecasts by Source 2022-2032

6.1. Segment Dashboard
6.2. Global Autologous Cell Therapy Market: Source Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Bone Marrow
- 6.2.2. Peripheral Blood
- 6.2.3. Adipose Tissue
- 6.2.4. Others

Chapter 7. Global Autologous Cell Therapy Market Size & Forecasts by End-Use 2022-2032

7.1. Segment Dashboard
7.2. Global Autologous Cell Therapy Market: End-Use Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Hospitals
- 7.2.2. Academics & Research
- 7.2.3. Others

Chapter 8. Global Autologous Cell Therapy Market Size & Forecasts by Region 2022-2032

8.1. North America Autologous Cell Therapy Market
- 8.1.1. U.S. Autologous Cell Therapy Market
  - 8.1.1.1. Application breakdown size & forecasts, 2022-2032
  - 8.1.1.2. Source breakdown size & forecasts, 2022-2032
  - 8.1.1.3. End-Use breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Autologous Cell Therapy Market
  - 8.1.2.1. Application breakdown size & forecasts, 2022-2032
  - 8.1.2.2. Source breakdown size & forecasts, 2022-2032
  - 8.1.2.3. End-Use breakdown size & forecasts, 2022-2032
8.2. Europe Autologous Cell Therapy Market
- 8.2.1. UK Autologous Cell Therapy Market
  - 8.2.1.1. Application breakdown size & forecasts, 2022-2032
  - 8.2.1.2. Source breakdown size & forecasts, 2022-2032
  - 8.2.1.3. End-Use breakdown size & forecasts, 2022-2032
- 8.2.2. Germany Autologous Cell Therapy Market
  - 8.2.2.1. Application breakdown size & forecasts, 2022-2032
  - 8.2.2.2. Source breakdown size & forecasts, 2022-2032
  - 8.2.2.3. End-Use breakdown size & forecasts, 2022-2032
- 8.2.3. France Autologous Cell Therapy Market
  - 8.2.3.1. Application breakdown size & forecasts, 2022-2032
  - 8.2.3.2. Source breakdown size & forecasts, 2022-2032
  - 8.2.3.3. End-Use breakdown size & forecasts, 2022-2032
- 8.2.4. Spain Autologous Cell Therapy Market
  - 8.2.4.1. Application breakdown size & forecasts, 2022-2032
  - 8.2.4.2. Source breakdown size & forecasts, 2022-2032
  - 8.2.4.3. End-Use breakdown size & forecasts, 2022-2032
- 8.2.5. Italy Autologous Cell Therapy Market
  - 8.2.5.1. Application breakdown size & forecasts, 2022-2032
  - 8.2.5.2. Source breakdown size & forecasts, 2022-2032
  - 8.2.5.3. End-Use breakdown size & forecasts, 2022-2032
- 8.2.6. Rest of Europe Autologous Cell Therapy Market
  - 8.2.6.1. Application breakdown size & forecasts, 2022-2032
  - 8.2.6.2. Source breakdown size & forecasts, 2022-2032
  - 8.2.6.3. End-Use breakdown size & forecasts, 2022-2032
8.3. Asia-Pacific Autologous Cell Therapy Market
- 8.3.1. China Autologous Cell Therapy Market
  - 8.3.1.1. Application breakdown size & forecasts, 2022-2032
  - 8.3.1.2. Source breakdown size & forecasts, 2022-2032
  - 8.3.1.3. End-Use breakdown size & forecasts, 2022-2032
- 8.3.2. India Autologous Cell Therapy Market
  - 8.3.2.1. Application breakdown size & forecasts, 2022-2032
  - 8.3.2.2. Source breakdown size & forecasts, 2022-2032
  - 8.3.2.3. End-Use breakdown size & forecasts, 2022-2032
- 8.3.3. Japan Autologous Cell Therapy Market
  - 8.3.3.1. Application breakdown size & forecasts, 2022-2032
  - 8.3.3.2. Source breakdown size & forecasts, 2022-2032
  - 8.3.3.3. End-Use breakdown size & forecasts, 2022-2032
- 8.3.4. Australia Autologous Cell Therapy Market
  - 8.3.4.1. Application breakdown size & forecasts, 2022-2032
  - 8.3.4.2. Source breakdown size & forecasts, 2022-2032
  - 8.3.4.3. End-Use breakdown size & forecasts, 2022-2032
- 8.3.5. South Korea Autologous Cell Therapy Market
  - 8.3.5.1. Application breakdown size & forecasts, 2022-2032
  - 8.3.5.2. Source breakdown size & forecasts, 2022-2032
  - 8.3.5.3. End-Use breakdown size & forecasts, 2022-2032
- 8.3.6. Rest of Asia Pacific Autologous Cell Therapy Market
  - 8.3.6.1. Application breakdown size & forecasts, 2022-2032
  - 8.3.6.2. Source breakdown size & forecasts, 2022-2032
  - 8.3.6.3. End-Use breakdown size & forecasts, 2022-2032
8.4. Latin America Autologous Cell Therapy Market
- 8.4.1. Brazil Autologous Cell Therapy Market
  - 8.4.1.1. Application breakdown size & forecasts, 2022-2032
  - 8.4.1.2. Source breakdown size & forecasts, 2022-2032
  - 8.4.1.3. End-Use breakdown size & forecasts, 2022-2032
- 8.4.2. Mexico Autologous Cell Therapy Market
  - 8.4.2.1. Application breakdown size & forecasts, 2022-2032
  - 8.4.2.2. Source breakdown size & forecasts, 2022-2032
  - 8.4.2.3. End-Use breakdown size & forecasts, 2022-2032
- 8.4.3. Rest of Latin America Autologous Cell Therapy Market
  - 8.4.3.1. Application breakdown size & forecasts, 2022-2032
  - 8.4.3.2. Source breakdown size & forecasts, 2022-2032
  - 8.4.3.3. End-Use breakdown size & forecasts, 2022-2032
8.5. Middle East & Africa Autologous Cell Therapy Market
- 8.5.1. Saudi Arabia Autologous Cell Therapy Market
  - 8.5.1.1. Application breakdown size & forecasts, 2022-2032
  - 8.5.1.2. Source breakdown size & forecasts, 2022-2032
  - 8.5.1.3. End-Use breakdown size & forecasts, 2022-2032
- 8.5.2. South Africa Autologous Cell Therapy Market
  - 8.5.2.1. Application breakdown size & forecasts, 2022-2032
  - 8.5.2.2. Source breakdown size & forecasts, 2022-2032
  - 8.5.2.3. End-Use breakdown size & forecasts, 2022-2032
- 8.5.3. Rest of Middle East & Africa Autologous Cell Therapy Market
  - 8.5.3.1. Application breakdown size & forecasts, 2022-2032
  - 8.5.3.2. Source breakdown size & forecasts, 2022-2032
  - 8.5.3.3. End-Use breakdown size & forecasts, 2022-2032

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
- 9.1.1 Company 1
- 9.1.2 Company 2
- 9.1.3 Company 3
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. BrainStorm Cell Therapeutics
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Holostem Terapie Avanzate S.R.L
- 9.3.3. Pharmicell Co. Inc
- 9.3.4. Opexa Therapeutics
- 9.3.5. Caladrius Biosciences Inc
- 9.3.6. U.S. Stem Cell Inc
- 9.3.7. Lonza
- 9.3.8. Bristol Myers Squibb
- 9.3.9. Novartis
- 9.3.10. Autolus Therapeutics

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes